A Phase 1 interventional study of Acalabrutinib in COVID-19, sponsored by Acerta Pharma BV. Terminated at 4 sites in Brazil. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2021-11-17.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in COVID-19 by AstraZeneca — 1 open to participants now, 1 under way, 1 of them phase 3. COVID-19 · AstraZeneca.
Among the 43 studies in COVID-19 by AstraZeneca, this one is the 25th largest by enrollment of the 26 interventional ones that give a count, is one of 12 that started in 2020, is one of 9 in phase 1, and was the 5th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →1 of the 43 studies in COVID-19 by AstraZeneca is open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Australia and 36 more countries
Ages 18+
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 8 · Phase 3 9 · Phase 4 1
First in 2020; this study’s year is marked. 12 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 147 across the 26 interventional studies, 4,232 across the 15 observational. Of the 38 that completed or were terminated, 17 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
1 of the studies in COVID-19 by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies in COVID-19 by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study D822FC00005 will investigate the Phamacokinetics, Safety and tolerability of Acalabrutinib suspension when delivered via a nasogastric tube and co-administered with a Proton Pump Inhibitor, in the treatment of COVID-19.
This study is to support the ongoing clinical development of acalabrutinib (CALQUENCE®) in hospitalized COVID-19 patients. Because many COVID-19 patients may be unable to swallow capsules due to respiratory failure (eg, they may require endotracheal intubation for ventilator support and Naso Gastric tube placement), it is important to have a clinically acceptable method to administer acalabrutinib (capsules) via NG tube. Furthermore, many hospitalized patients are placed on high doses of proton pump inhibitors (PPIs) (also commonly known as antacid medication). This study is designed to determine the Pharmaco Kinetics (effect of body/ bodily systems on the drug), safety and tolerability of acalabrutinib suspension, when coadministered with a PPI, in participants with confirmed SARS-CoV-2 infection requiring hospitalization due to respiratory failure, attributable to COVID-19 pneumonia and who have an Nasogastric (NG) tube in place.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who are hospitalized with coronavirus (SARS-CoV-2) infection, confirmed by PCR test or other commercial or public health assay in any specimen, as documented by either of the following:
PCR positive in sample collected ≥ 72 hours prior to first dose (but no more than 14 days prior to first dose), documented inability to obtain a repeat sample (eg, due to lack of testing supplies, limited testing capacity, results taking > 24 hours, etc), AND progressive disease suggestive of ongoing SARS-CoV-2 infection 3 Evidence of respiratory failure attributable to COVID-19 pneumonia (documented radiographically) before enrollment 4 Nasogastric tube or other types of oral or percutaneous gastric feeding tube; placement must be radiographically confirmed and expected to remain in place, as judged by the investigator, for a minimum of 3 days after study enrolment.
5 Has received treatment with PPIs (eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole) for a minimum of 24 hours immediately prior to enrollment; any PPI will be permitted, provided it meets the minimum equivalent daily dose of 20 mg rabeprazole.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single Arm
Drug: Acalabrutinib
Acalabrutinib (CALQUENCE®) is a covalent BTK inhibitor
Also known as: CALQUENCE®
Area Under the Concentration-time Curve From 0 to 12 Hours (AUC12h) for Acalabrutinib and ACP-5862 in Visit 1 (Day 1), Visit 2 (Day 2), and Visit 3 (Day 5)
To summarize the PK parameter AUC12h of Acalabrutinib/ACP-5862 in single arm, Acalabrutinib + BSC + PPI
Time frame: pre-dose and 0.5, 1, 2, 4, 6, and 12 hours in visit 1 on Day 1, visit 2 on Day 2 and visit 3 on Day 5
Area Under the Concentration-time Curve From 0 to Time to Last Quantifiable Concentration (AUClast) for Acalabrutinib and ACP-5862 in Visit 1 (Day 1), Visit 2 (Day 2), and Visit 3 (Day 5)
To summarize the PK parameter AUClast for Acalabrutinib/ACP-5862 in single arm, Acalabrutinib + BSC +PPI
Time frame: pre-dose and 0.5, 1, 2, 4, 6, and 12 hours in visit 1 on Day 1, visit 2 on Day 2 and visit 3 on Day5
Maximum Observed Plasma Concentration (Cmax) for Acalabrutinib and ACP-5862 in Visit 1 (Day 1), Visit 2(Day2) and Visit 3 (Day 5)
To summarize the PK parameter Cmax of Acalabrutinib/ACP-5862 in single arm, Acalabrutinib + BSC +PPI
Time frame: pre-dose and 0.5, 1, 2, 4, 6, and 12 hours in visit 1(Day 1), visit 2(Day 2) and visit 3(Day 5)
Approximately 20 participants were planned to be enrolled to have at least 16 evaluable participants.
| Milestone | Acalabrutinib + BSC + PPI |
|---|---|
| Started | 9 |
| Completed | 7 |
| Not completed | 2 |
| Withdrew: Death | 2 |
To summarize the PK parameter AUC12h of Acalabrutinib/ACP-5862 in single arm, Acalabrutinib + BSC + PPI
| h·ng/mL | Acalabrutinib + BSC + PPI, Visit 1 on Day 1 | Acalabrutinib + BSC + PPI, Visit 2 on Day 2 | Acalabrutinib + BSC + PPI, Visit 3 on Day 5 |
|---|---|---|---|
| Acalabrutinib | 524.7 ± 86.5 | 496.5 ± 58.0 | 201.1 ± 95.3 |
| ACP-5862 | 832.8 ± 29.3 | 1228.0 ± 35.1 | 867.1 ± 43.1 |
To summarize the PK parameter AUClast for Acalabrutinib/ACP-5862 in single arm, Acalabrutinib + BSC +PPI
| h·ng/mL | Acalabrutinib + BSC + PPI, Visit 1 on Day 1 | Acalabrutinib + BSC + PPI, Visit 2 on Day 2 | Acalabrutinib + BSC + PPI, Visit 3 on Day 5 |
|---|---|---|---|
| Acalabrutinib | 490.1 ± 64.8 | 493.7 ± 58.4 | 193.7 ± 96.6 |
| ACP-5862 | 731.0 ± 38.4 | 1228.0 ± 35.1 | 827.9 ± 46.2 |
To summarize the PK parameter Cmax of Acalabrutinib/ACP-5862 in single arm, Acalabrutinib + BSC +PPI
| ng/mL | Acalabrutinib + BSC + PPI, Visit 1 on Day 1 | Acalabrutinib + BSC + PPI, Visit 2 on Day 2 | Acalabrutinib + BSC + PPI, Visit 3 on Day 5 |
|---|---|---|---|
| Acalabrutinib | 297.0 ± 56.7 | 307.9 ± 51.3 | 167.1 ± 88.7 |
| ACP-5862 | 213.1 ± 62.9 | 316.9 ± 38.5 | 324.2 ± 47.6 |
Collected over 2 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Acalabrutinib + BSC + PPI | 2/9 (22.2%) | 5/9 (55.6%) | 9/9 (100%) |
| Event | Acalabrutinib + BSC + PPI |
|---|---|
| Pneumonia bacterialInfections and infestations | 2/9 |
| Device related infectionInfections and infestations | 1/9 |
| PneumoniaInfections and infestations | 1/9 |
| Transaminases increasedInvestigations | 1/9 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/9 |
| HypotensionVascular disorders | 1/9 |
| Event | Acalabrutinib + BSC + PPI |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 5/9 |
| LymphopeniaBlood and lymphatic system disorders | 2/9 |
| Abdominal distensionGastrointestinal disorders | 2/9 |
| PneumoniaInfections and infestations | 2/9 |
| Pneumonia bacterialInfections and infestations | 2/9 |
| Alanine aminotransferase increasedInvestigations | 2/9 |
| Aspartate aminotransferase increasedInvestigations | 2/9 |
| HypernatraemiaMetabolism and nutrition disorders | 2/9 |
| HypophosphataemiaMetabolism and nutrition disorders | 2/9 |
| Peripheral motor neuropathyNervous system disorders | 2/9 |
| Age, Continuous(Years) | Acalabrutinib + BSC + PPI |
|---|---|
| Mean | 61.3 ± 10.7 |
| Age, Customized(Participants) | Acalabrutinib + BSC + PPI |
|---|---|
| < 65 years | 4 |
| >= 65 years | 5 |
| Sex: Female, Male(Participants) | Acalabrutinib + BSC + PPI |
|---|---|
| Female | 4 |
| Male | 5 |
| Ethnicity (NIH/OMB)(Participants) | Acalabrutinib + BSC + PPI |
|---|---|
| Hispanic or Latino | 7 |
| Not Hispanic or Latino | 2 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Acalabrutinib + BSC + PPI |
|---|---|
| WHITE | 7 |
| BLACK OR AFRICAN AMERICAN | 2 |
| AMERICAN INDIAN OR ALASKA NATIVE | 0 |
| ASIAN | 0 |
| NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 0 |
| OTHER | 0 |
| NOT REPORTED | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Sep 2020 to primary completion in Nov 2020, 1 month.
Results were first posted in Nov 2021, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acalabrutinib